ASIA-PACIFIC CANCER BIOMARKER MARKET 2017-2025

ASIA-PACIFIC CANCER BIOMARKER MARKET 2017-2025

  • August 2017 •
  • 75 pages •
  • Report ID: 5067719
KEY FINDINGS
The Asia-Pacific cancer biomarkers market is expected to speed up its growth with a CAGR of 15.73% for the years 2017-2025, generating a net worth of $8831 million. India is the fastest growing market in the Asia-Pacific region.

MARKET INSIGHTS
The market is mainly categorized into diseases and discovery & diagnostics, and further into their sub-segments. The adoption of western lifestyles in developing Asia Pacific regions, prevailing high population, and the growing cancer research in the Asian countries are majorly responsible for accelerating the market growth. However, the low estimated rate for successful clinical trials and the various technical issues related to cancer biomarkers are expected to prove challenging for the market growth.

COMPETITIVE INSIGHTS
Some of the established companies in this market are Qiagen N.V, Agilent Technologies, Ambrilia Biopharma Inc, Agendia N. Roche Diagnostics Ltd, Astellas Pharma Inc, Abbott Laboratories, Biomoda Inc, and Illumina, Inc, V.